High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.

Simple item page
dc.contributor.affiliationDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
dc.contributor.affiliationDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.
dc.contributor.affiliationLiver Center and Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
dc.contributor.affiliationSchool of Medicine, University of Zambia, Lusaka, Zambia.
dc.contributor.affiliationDivision of Infectious Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
dc.contributor.affiliationInstitute of Social and Preventative Medicine, University of Bern, Bern, Switzerland.
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
dc.contributor.affiliationMinistry of Health, Lusaka, Zambia.
dc.contributor.affiliationCentre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorChihota BV
dc.contributor.authorWandeler G
dc.contributor.authorChilengi R
dc.contributor.authorMulenga L
dc.contributor.authorChung RT
dc.contributor.authorBhattacharya D
dc.contributor.authorEgger M
dc.contributor.authorVinikoor MJ
dc.date.accessioned2025-07-10T11:07:19Z
dc.date.issued2020-Jan-02
dc.description.abstractAmong 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.
dc.identifier.doi10.1093/infdis/jiz450
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/11088
dc.identifier.uri.pubmedhttps://pubmed.ncbi.nlm.nih.gov/31613956/
dc.sourceThe Journal of infectious diseases
dc.titleHigh Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.

Files

Collections

Published